|
|
|
|
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
CORONA, Calif., Nov.25 (HSMN NewsFeed) -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are...
|
|
|
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
CORONA, Calif., Nov.25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being...
|
|
|
Watson signs pact to acquire products related to Teva's proposed acquisition of Barr
Watson Pharmaceuticals, Inc, a leading specialty pharmaceutical company, announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva...
|
|
|
Watson Enters Into Agreement To Acquire Products Related To Teva's Proposed Acquisition Of Barr
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, recently announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between...
|
|
|
Watson Pharmaceuticals (WPI) Agrees to Acquire Portfolio of Generic Pharma Products Following Teva/Barr Merger
Watson Pharmaceuticals, Inc.(NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the proposed merger between Teva Pharmaceutical Industries,...
|
|
|
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Cyclosporine Capsules and Liquid Desmopressin Acetate Tablets Glipizide/Metformin HCl Tablets Mirtazapine Orally Disintegra Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr.
|
|
|
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
CORONA, Calif., Nov.25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being...
|
|
|
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
CORONA, Calif., Nov.25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (WPI), a leading specialty pharmaceutical company, today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are...
|
|
|
Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Brea
- Cougar Biotechnology, Inc.announced that the first patient was enrolled in a Phase I/II clinical trial of the Company's drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase...
|
|
|
Cougar Biotechnology Announces Initiation of Phase I/II Trial ofCB7630 (Abiraterone Acetate) in Advanced Breas
- Cougar Biotechnology, Inc.(NASDAQ: CGRB) today announced that the first patient was enrolled in a Phase I/II clinical trial of the Company's drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme...
|
|
|
Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Brea
- Cougar Biotechnology, Inc.(NASDAQ: CGRB) today announced that the first patient was enrolled in a Phase I/II clinical trial of the Companys drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme...
|
|
|
BTG Licensee Cougar Biotechnology Initiates Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Breas
Get Instant Access to our News Archive For more than 20 years, executives like you have relied on Canon Communications Pharmaceutical Media Group for the business, marketing, and clinical research information needed to make informed business...
|
|
|
Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Brea
Cougar Biotechnology, Inc.(NASDAQ: CGRB) today announced that the first patient was enrolled in a Phase I/II clinical trial of the Companys drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme...
|
|
|
Cougar Biotechnology Announces Initiation of Phase I/II Trial of CB7630 (Abiraterone Acetate) in Advanced Brea
-Cougar Biotechnology, Inc.(NASDAQ: CGRB) today announced that the first patient was enrolled in a Phase I/II clinical trial of the Companys drug candidate CB7630 (abiraterone acetate), an orally active inhibitor of the steroidal enzyme...
|
|
|
::: Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. (BULLETIN BOARD: KURU) , a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
/Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial results for the third...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. , a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
, a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial results for the third quarter ended September 30, 2008.Third Quarter 2008 Highlights ...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. , a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
, a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial results for the third quarter ended September 30, 2008.Third Quarter 2008 Highlights ...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
Feature News Text hiding to spacing Run Biotechnology, Inc.Announces Third Quarter 2008 Results HAIKOU, China, Nov. 14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. (OTC Bulletin Board: KURU), a leading bio...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. , a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. , a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs,...
|
|
|
Kun Run Biotechnology, Inc. Announces Third Quarter 2008 Results
HAIKOU, China, Nov.14 /Xinhua-PRNewswire-FirstCall/ -- Kun Run Biotechnology, Inc. (OTC Bulletin Board: KURU), a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs,...
|
